Protein C-ets-1 (ETS1) (ETS1)

Protein C-ets-1 (ETS1) is the founding member of the ETS family of transcription factors, defined by a conserved DNA-binding domain that recognizes the GGAA/T core sequence [1, 4]. It functions as a master regulator of diverse biological processes, including cellular proliferation, apoptosis, and the development of the vascular and immune systems [3]. In oncology, ETS1 is frequently overexpressed and acts as a pro-oncogenic factor by driving the expression of matrix metalloproteinases and vascular endothelial growth factor, thereby promoting tumor invasion and angiogenesis [5]. Beyond cancer, ETS1 is a critical genetic risk factor for systemic lupus erythematosus (SLE), where its deficiency or dysfunction leads to the loss of immune tolerance and increased inflammatory cytokine production [3]. Therapeutic targeting of ETS1 is an active area of research, focusing on small molecules that can disrupt its DNA-binding activity or its recruitment of transcriptional co-activators [5]. Although direct inhibitors are primarily in the preclinical stage, they represent a promising approach for treating both metastatic cancers and refractory autoimmune conditions [4, 5]. Challenges in targeting ETS1 include its high structural homology with other ETS family members and its essential role in normal hematopoiesis, which necessitates high specificity to avoid systemic toxicity [3].

Other names

ETS-1c-ets-1p54EWSR2ETS proto-oncogene 1, transcription factor

Inhibition of DNA binding to the ETS-binding site (EBS) or disruption of protein-protein interactions with transcriptional co-activators [3, 5].